About this trial
This trial is looking at a new way to treat certain types of metastatic cancer using immune cells from the patients' own tumors. The goal is to see if these specially selected immune cells can help shrink tumors in patients with cancers of the digestive tract, bladder, breast, or ovaries. Researchers also want to find out if this treatment is safe and effective for these patients.
This study is in Phase 2, which means it is testing how well the treatment works and its safety. It is FDA-regulated and aims to include around 332 participants.
Who can join
Adults aged 18 to 72 can join if they have certain types of metastatic cancer that have not responded to standard treatments. This includes cancers of the digestive system, bladder, breast, or ovaries. The trial team will confirm if each person meets the eligibility requirements.
Conditions
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will first undergo tests and possibly surgery to collect tumor samples. They will then receive treatment that includes a type of immune cell therapy along with other medicines. Some patients will also receive a medication called pembrolizumab. Everyone will receive the treatment through a structured plan, but not all will receive the same type of immune cells.
Where
This trial is running at 1 location in the United States. It is currently recruiting.
National Institutes of Health Clinical Center
Bethesda, Maryland